| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRY1 |
| Uniprot No | P07477 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-247 aa |
| 活性数据 | IVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS |
| 分子量 | 31.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人TRY1(胰蛋白酶原1)相关的文献示例(注意：以下信息为示例性内容，具体文献可能需要根据实际数据库检索调整)：
---
1. **文献名称**: *Expression and Purification of Recombinant Human Trypsinogen 1 in Escherichia coli*
**作者**: Zhang Y. et al.
**摘要**: 研究报道了通过大肠杆菌表达系统高效生产重组人胰蛋白酶原1(TRY1)的方法，优化了诱导条件与纯化策略，活性检测显示重组蛋白具有与天然酶类似的酶切功能。
2. **文献名称**: *Crystal Structure of Recombinant Human Anionic Trypsin (TRY1) in Complex with Inhibitor*
**作者**: Smith J., Brown K.
**摘要**: 通过X射线晶体学解析了重组人TRY1与抑制剂的复合物结构，揭示了其底物结合位点的构象特征，为设计胰蛋白酶靶向药物提供了结构基础。
3. **文献名称**: *Functional Characterization of Recombinant Trypsin 1 in Chronic Pancreatitis Models*
**作者**: Lee S. et al.
**摘要**: 利用重组人TRY1研究其在慢性胰腺炎中的病理机制，发现其异常活化可加剧胰腺组织损伤，提示TRY1可能作为治疗靶点。
---
**提示**：实际文献检索建议使用PubMed或Web of Science，结合关键词“recombinant human trypsinogen 1”或“TRY1 protein”筛选近期研究。若研究较少，可扩展至胰蛋白酶家族或重组表达技术相关文献。
Recombinant human tyrosinase-related protein 1 (TYRP1), also known as TRY1. is a melanocyte-specific glycoprotein involved in melanin biosynthesis. As a member of the tyrosinase enzyme family, it shares structural homology with tyrosinase but exhibits distinct catalytic functions. TRY1 primarily stabilizes tyrosinase activity and modulates the oxidation of 5.6-dihydroxyindole-2-carboxylic acid (DHICA) during eumelanin production. It localizes to melanosomes and requires interactions with other melanogenic enzymes for optimal function.
Genetically expressed in heterologous systems like mammalian cells or bacteria, recombinant TRY1 enables studies of its structural characteristics, post-translational modifications, and enzymatic mechanisms. Mutations in the TYRP1 gene are linked to oculocutaneous albinism type 3 (OCA3), a disorder characterized by reduced pigmentation and vision abnormalities. Recombinant TRY1 serves as a critical tool for investigating disease pathogenesis and screening potential therapeutic compounds.
Beyond albinism research, TRY1 has implications in melanoma biology, as its expression correlates with aggressive tumor phenotypes. The recombinant protein aids in developing targeted therapies and immunotherapies against TRY1-positive cancers. Recent advances in protein engineering have improved TRY1's solubility and stability, facilitating crystallization studies and inhibitor design. Its role in regulating oxidative stress responses within melanocytes further expands its relevance to dermatological and neurodegenerative research. Ongoing studies continue to unravel TRY1's pleiotropic functions in pigmentation and disease.
×
